A $137M Backlog, No Debt, and Profits Rising Faster Than Sales. About Three Years of Sales Already on the Books.

A designer and manufacturer of specialized power supplies and transformers for military and industrial customers, with a backlog of $137.1M at March 31, 2026, roughly three times its FY2025 net sales of $43.95M. Net income rose 40% to $8.14M in FY2025, nine-month FY2026 net income of $7.84M has already reached 96% of that total on lower sales, and the company carries no debt. The backlog is the thesis; the pace of its conversion is the risk.

Analysis

Espey Mfg. & Electronics designs and produces specialized power supplies and transformers for military and industrial customers from its facility in Saratoga Springs, New York, and its shares trade on the NYSE American. The business is small and specific. FY2025 net sales, for the year ended June 30, 2025, were $43.95M, up 13.5% from $38.74M, and net income rose 40% to $8.14M, or $3.02 per diluted share. The number that defines the company sits above its revenue line. Backlog stood at $139.7M at the end of FY2025, up from $97.2M a year earlier, and was $137.1M at March 31, 2026.

That backlog is the strategic fact. At roughly three times annual sales, it represents years of contracted production for customers building military platforms, and management said at least $26.8M of the December 31, 2025 backlog was expected to ship during FY2026. New orders in FY2025 were $86.4M, up 65% from $52.4M, which is how the backlog climbed so far in one year. Orders are lumpy by nature: FY2026 new orders through nine months were $30.0M, against $75.1M in the same period a year earlier, which is why the backlog has leveled rather than kept rising. A defense electronics supplier lives on multi-year program awards, and a comparison against a record order year says more about the record than about the current year.

The Human Translation: Espey builds the power equipment that goes inside military hardware, and it has about three years of orders waiting to be built. It now makes more money on each order than it used to, it owes nothing, and it pays a regular dividend with an occasional special one on top. The risk is that orders arrive in irregular waves, so some quarters look weak even when the business underneath is fine.

Profitability is improving faster than sales, and that is the core of the operating thesis. Nine-month FY2026 net sales were $32.65M, slightly below the prior year's $34.35M, yet nine-month net income rose to $7.84M, or $2.74 per diluted share, from $5.21M, or $1.95. Third-quarter net income was $2.86M, or $0.99 per diluted share, against $1.70M a year earlier, on sales of $11.42M against $10.30M. Management attributes the margin expansion to a more favorable product mix, labor efficiencies, negotiated savings on materials, and operating leverage. A supplier earning more on flat revenue is repricing its work, not just shipping more of it.

The timing variable deserves plain treatment because it drives most of the quarter-to-quarter noise. Sales in the first half of FY2026 fell to $21.23M from $24.05M, and management attributed the decline to a timing shift in certain deliverables caused by factors outside its control rather than to lost business. Much of the company's work runs on milestone-based, engineering-heavy, fixed-price contracts, which means revenue is recognized as programs reach technical and delivery milestones. Quarters will be uneven by construction; the backlog is what smooths the view. Reading any single quarter in isolation misreads the company in both directions, overreacting to a slow shipment period and to a strong one alike.

Reading a backlog correctly matters more here than in most names. Backlog is contracted work not yet recognized as revenue, and it converts on the customer's program schedule, not the supplier's. A backlog that holds near $137M while quarterly sales run near $11M means the company is replacing what it ships; a backlog that falls quarter after quarter while sales hold means it is consuming its visibility faster than it rebuilds it. Through March 2026 the book was essentially level with the prior year's $138.0M, which is the reading the desk would expect in a year that followed record orders.

Customer concentration is the most important risk, and the company discloses it. In the six months ended December 31, 2025, four significant customers accounted for about 61% of total sales. For a defense supplier that is structural rather than alarming, since the buyers are prime contractors and government programs, but it means a single program delay, budget reallocation, or contract renewal can move a year's results. The balance sheet is the reason that risk is survivable.

The balance sheet carries no debt, and working capital was about $48.9M at December 31, 2025. The company paid a special dividend of $0.75 per share during the first half of FY2026 on top of its regular quarterly dividend of $0.25 per share. A manufacturer with lumpy revenue and concentrated customers needs exactly this posture: enough liquidity to fund inventory and engineering through slow quarters without borrowing at a 5% ten-year, and enough surplus to return cash when a strong year allows it.

The defense backdrop is supportive, and the desk describes it without overstating it. The weekly roundup has tracked a year of conflict in the Middle East, crude above $100, and a policy environment focused on military readiness, all of which support demand for the platforms Espey's products go into. What a budget does not do is set the timing of any individual award. The FY2025 order surge showed what a strong award year looks like, and the slower FY2026 pace shows the other half of the cycle. Both are normal for the category.

The competitive position is niche by design. Espey builds custom, rugged power conversion equipment to military specifications, which requires qualification on each program and creates switching costs once a supplier is designed in. That is why a company this size can hold multi-year positions alongside much larger suppliers. The same specificity limits its addressable market, and growth depends on winning new program positions rather than on selling more of a standard product.

Management has been in place through the rebuild of the company's results. In FY2021 the company lost money on $27.7M of sales; in FY2022 it earned $1.27M on $32.1M; by FY2025 it earned $8.14M on $43.95M. That progression, from a loss to a net margin near 19% in four years, came from the operating work management keeps describing: labor stability, cost control, contract discipline, and a better product mix. The FY2022 release credited stabilized labor and progress on problem contracts; the FY2026 releases credit mix and efficiency. Under the same chief executive, the story has been consistent for four years.

On valuation, the desk makes no price targets. The public record supports two observations. Nine-month FY2026 earnings of $2.74 per diluted share are already close to the full-year FY2025 figure of $3.02, with a fourth quarter still to report. And the backlog, at $137.1M, is about three times the most recent full-year sales, which gives unusual visibility for a company this size. Neither observation removes the timing risk; both explain why the company deserves to be read on its backlog rather than on any single quarter.

The rate backdrop matters here in a specific way. The weekly roundup has followed the ten-year Treasury through 5% and a September rate hike, and higher rates reprice the financing window for every small company that needs capital. Espey does not need it. A debt-free manufacturer with a multi-year order book funds its own inventory and engineering, and in this regime that separates it from peers that borrow to bridge the gap between an order and the payment for it.

The quarterly figures show why the company should be read over a year rather than a quarter. Net sales were $9.09M in the first quarter of FY2026, $12.14M in the second, and $11.42M in the third, while net income held between $2.17M and $2.86M in every one of them. A sales swing of more than $3M between adjacent quarters barely moved profit. That stability on uneven revenue is the signature of better pricing and cost control rather than a volume story.

The backlog history makes the scale of the last several years clear. It stood at $65.6M at June 30, 2021 and $76.8M a year later, reached $97.2M by June 2024 and $139.7M by June 2025, and peaked at $141.1M at September 30, 2025. Over four years the company roughly doubled the work it has under contract while turning a net loss into a net margin near 19%. The chart in this dossier tracks the most recent eight quarter-ends, from $97.2M to $137.1M.

Order intake shows the same lumpiness at the annual level. New orders were $38.5M in FY2021, $43.2M in FY2022, $52.4M in FY2024, and $86.4M in FY2025. Against that history, the $30.0M of new orders in the first nine months of FY2026 is below the record pace but broadly in line with the company's years before the surge on an annualized basis, which is the more useful comparison. A backlog that converts at roughly $44M of sales a year needs orders of about that size to hold steady, and the fourth quarter of FY2026 will show whether the year closes near that mark.

The dividend record adds a signal of its own. The regular dividend of $0.25 per quarter sums to $1.00 a year against FY2025 earnings of $3.02 per diluted share, a payout that leaves most earnings in the business, and the $0.75 special dividend came right after the record FY2025. A board that declares a special dividend following a record year, while holding a backlog near three times sales, is signaling that current cash generation exceeds what the order book requires. The desk treats future dividend decisions as part of the checkpoint set for exactly that reason.

The scenario map has three branches. In the first, new orders recover toward the FY2025 pace, the backlog resumes growth, and margins hold as production converts it, compounding earnings off a larger revenue base. In the second, orders stay slower but the existing backlog converts on schedule, and the company earns well on a steady book while returning cash. In the third, a program delay or cancellation among its concentrated customers hits sales and backlog in the same period, and the thesis is retested on the strength of its balance sheet. The desk names the branches so each filing can be read against them.

The checkpoint set, stated fully. First, the FY2026 annual report, due shortly, which shows full-year sales, net income, and the backlog at June 30, 2026. Second, new orders each quarter, the leading indicator of whether the backlog grows or shrinks from here. Third, gross margin and net income against sales, which confirm whether the margin gains are durable. Fourth, customer concentration disclosures and dividend decisions, the board's own read on cash generation. The thesis strengthens on renewed order growth with stable margins; it weakens if orders stay slow while the backlog shrinks. Each of those lines prints in a public filing on a fixed calendar.

The Human Translation

Espey makes power supplies and transformers that go inside military equipment. It has about $137M of orders waiting to be built, roughly three years of its sales, and it is making more profit on each dollar of sales than it used to. It has no debt and pays a dividend, with a special one in good years. Orders arrive unevenly and a few big customers make up most of its sales, so individual quarters can swing. The bet is on a debt-free supplier working through a large, long-dated order book.

Bottom Line

Watch the FY2026 annual report for the June 30 backlog and full-year earnings, then new orders each quarter. Backlog tells you how much work is secured; orders tell you whether it is being replaced. Margins confirm whether the profit gains are durable.

Quick Facts

More from the research desk: XTIA, DPRO, IIIN, and the full library